Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ441,54420,34
KB0,00
PKN42,5242,55-0,45
Msft0,20
Nokia3,56053,6265-0,22
IBM-6,49
Daimler AG48,67548,695-0,27
PFE-0,82
21.10.2020 1:38:59
Indexy online
AD Index online
select
AD Index online
 

  • 20.10.2020
Zoetis Inc, Ordinary, New York Consolidated (ZTS, NY Consolidated)
Závěr k 20.10.2020 Změna (%) Změna (USD) Objem obchodů (ks)
159,69 -0,19 -0,30 2 145 698
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 21.10.2020
Popis společnosti
Obecné informace
Název společnostiZoetis Inc
TickerZTS
Kmenové akcie:Ordinary Shares Class A
Kmenové akcie:Ordinary Shares Class B
RICZTS
ISIN-
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky30.06.2020
Počet zaměstnanců k 31.12.2019 10 600
Akcie v oběhu k 31.07.2020 475 144 704
Počet akcionářů k 31.12.2019 1 795
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice10 Sylvan Way
MěstoPARSIPPANY
PSČ07054-3825
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon19 738 227 000
Fax13026555049

Business Summary: Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.
Financial Summary: BRIEF: For the six months ended 30 June 2020, Zoetis Inc revenues increased 3% to $3.08B. Net income increased 17% to $800M. Revenues reflect US segment increase of 7% to $1.61B, The United States (U.S.) segment increase of 7% to $1.61B. Net income benefited from Restructuring charges decrease of 72% to $5M (expense), Interest Expense -Gross decrease of 1% to $119M (expense). Dividend per share increased from $0.33 to $0.40.
Odvětvová klasifikace
TRBC2012Veterinary Drugs
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSBiological Product (except Diagnostic) Manufacturing
SICPharmaceutical Preparations
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace: 21.10.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, DirectorKristin Peck4801.01.2020
Chief Financial Officer, Executive Vice PresidentGlenn David4818.08.201622.04.2014
Chief Human Resource Officer, Executive Vice President and Global OperationsRoxanne Lagano55
Executive Vice President, General Counsel, Corporate SecretaryHeidi Chen53
Executive Vice President, President - Research and DevelopmentCatherine Knupp59
Executive Vice President, President - Global Manufacturing and SupplyRoman Trawicki56